ATE323289T1 - Auf tsap6-bindungspartnern beruhendes screeningverfahren - Google Patents

Auf tsap6-bindungspartnern beruhendes screeningverfahren

Info

Publication number
ATE323289T1
ATE323289T1 AT01995786T AT01995786T ATE323289T1 AT E323289 T1 ATE323289 T1 AT E323289T1 AT 01995786 T AT01995786 T AT 01995786T AT 01995786 T AT01995786 T AT 01995786T AT E323289 T1 ATE323289 T1 AT E323289T1
Authority
AT
Austria
Prior art keywords
tsap6
binding partners
procedure based
screening procedure
methods
Prior art date
Application number
AT01995786T
Other languages
English (en)
Inventor
Robert Amson
Adam Telerman
Brent Passer
Original Assignee
Cerenis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerenis filed Critical Cerenis
Application granted granted Critical
Publication of ATE323289T1 publication Critical patent/ATE323289T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01995786T 2000-12-26 2001-12-24 Auf tsap6-bindungspartnern beruhendes screeningverfahren ATE323289T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0017027 2000-12-26
FR0102896 2001-09-18

Publications (1)

Publication Number Publication Date
ATE323289T1 true ATE323289T1 (de) 2006-04-15

Family

ID=32922195

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01995786T ATE323289T1 (de) 2000-12-26 2001-12-24 Auf tsap6-bindungspartnern beruhendes screeningverfahren

Country Status (2)

Country Link
US (1) US20040175772A1 (de)
AT (1) ATE323289T1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015194831A1 (ko) 2014-06-16 2015-12-23 이화여자대학교 산학협력단 TCTP 이량체형 IgE-의존성 히스타민 방출인자와 이의 수용체 간의 결합 억제제 및 이의 용도

Also Published As

Publication number Publication date
US20040175772A1 (en) 2004-09-09

Similar Documents

Publication Publication Date Title
DE69942827D1 (de) Verwendung der epothilons zur behandlung der krebs
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
ATE470439T1 (de) Verwendung von hif 1alfa modulatoren zur behandlung von krebs
EP1700120A4 (de) Marker für neuromyelitis optica
TW200716141A (en) Compositions and methods for treatment for neoplasms
ATE461220T1 (de) Anti-egfr-antikörper
BRPI0511070A (pt) compostos e processos para inibição da interação de proteìnas bcl com parceiros de ligação
EA200100573A1 (ru) Применение ингибитора циклооксигеназы-2, ингибитора матричной металлопротеиназы, противоопухолевого лекарственного средства и факультативно облучения в качестве комбинированного способа лечения неоплазии
DE602004015811D1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
TW200603828A (en) Treatment of disorders
WO2006019982A3 (en) Pin1-modulating compounds and methods of use thereof
HK1083220A1 (en) P53 binding polypeptide
EA200400235A1 (ru) Комбинированная терапия для лечения рака
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
EP1575989A4 (de) MIT PrP sp sc/sp WECHSELWIRKENDE MOLEKÜLE UND DEREN VERWENDUNG
MY153232A (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
IL151448A0 (en) Proteins
ATE410235T1 (de) Behandlung von ballastwasser
TW200637830A (en) Erastin and erastin binding proteins, and uses thereof
ATE323289T1 (de) Auf tsap6-bindungspartnern beruhendes screeningverfahren
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
DE60231971D1 (de) Ndet, und seine verwendung zur behandlung von krebs
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
MXPA05001690A (es) Estrategia de deteccion para farmacos anticancer.
WO2002052274A3 (fr) Procede de criblage base sur les partenaires de liaison de tsap6

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1346230

Country of ref document: EP

REN Ceased due to non-payment of the annual fee